



HAL
open science

Water-Soluble Gd(III)–Porphyrin Complexes Capable of Both Photosensitization and Relaxation Enhancement

Tamas Nemeth, Naoko Yoshizawa-Sugata, Agnes Pallier, Youichi Tajima, Yue Ma, Éva Tóth, Hisao Masai, Yoko Yamakoshi

► To cite this version:

Tamas Nemeth, Naoko Yoshizawa-Sugata, Agnes Pallier, Youichi Tajima, Yue Ma, et al.. Water-Soluble Gd(III)–Porphyrin Complexes Capable of Both Photosensitization and Relaxation Enhancement. *Chemical & Biomedical Imaging*, 2023, 1 (2), pp.157-167. 10.1021/cbmi.3c00007. hal-04288624

HAL Id: hal-04288624

<https://cnrs.hal.science/hal-04288624v1>

Submitted on 16 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Water-Soluble Gd(III)–Porphyrin Complexes Capable of Both Photosensitization and Relaxation Enhancement

Tamas Nemeth, Naoko Yoshizawa-Sugata, Agnes Pallier, Youichi Tajima, Yue Ma, Éva Tóth,* Hisao Masai,* and Yoko Yamakoshi*

Cite This: *Chem. Biomed. Imaging* 2023, 1, 157–167

Read Online

ACCESS |


Metrics & More

Article Recommendations

Supporting Information

ABSTRACT: With the aim of developing more stable Gd(III)–porphyrin complexes, two types of ligands **1** and **2** with carboxylic acid anchors were synthesized. Due to the N-substituted pyridyl cation attached to the porphyrin core, these porphyrin ligands were highly water-soluble and formed the corresponding Gd(III) chelates, **Gd-1** and **Gd-2**. **Gd-1** was sufficiently stable in neutral buffer, presumably due to the preferred conformation of the carboxylate-terminated anchors connected to nitrogen in the *meta* position of the pyridyl group helping to stabilize Gd(III) complexation by the porphyrin center. ¹H NMRD (nuclear magnetic relaxation dispersion) measurements on **Gd-1** revealed high longitudinal water proton relaxivity ($r_1 = 21.2 \text{ mM}^{-1} \text{ s}^{-1}$ at 60 MHz and 25 °C), which originates from slow rotational motion resulting from aggregation in aqueous solution. Under visible light irradiation, **Gd-1** showed extensive photoinduced DNA cleavage in line with efficient photoinduced singlet oxygen generation. Cell-based assays revealed no significant dark cytotoxicity of **Gd-1**, while it showed sufficient photocytotoxicity on cancer cell lines under visible light irradiation. These results indicate the potential of this Gd(III)–porphyrin complex (**Gd-1**) as a core for the development of bifunctional systems acting as an efficient photodynamic therapy photosensitizer (PDT-PS) with magnetic resonance imaging (MRI) detection capabilities.

KEYWORDS: Singlet oxygen generation, relaxivity, Gd(III) chelate, water-soluble porphyrin, photocytotoxicity



INTRODUCTION

Porphyrins are one of the most common core molecules as photosensitizers (PSs), both in biology (e.g., photosynthesis) and in material sciences (e.g., photovoltaic systems). Since these polyaromatic molecules are often hydrophobic, especially as synthetic derivatives, much effort has been made to develop water-soluble porphyrin materials by adding suitable water-soluble moieties. This is particularly important for biological applications such as photodynamic therapies (PDTs). Indeed, most of the FDA-approved PDT-PS molecules are porphyrin-based compounds, including Photofrin, Foscan, Laserphyrin, and Motezafin lutetium,¹ and can be excited by irradiation with visible light to generate reactive oxygen species (ROS), as active species to treat the diseased tissues. Key considerations in the development of such PDT-PSs include (1) they can be excited by a long wavelength of light that is less toxic and can penetrate more deeply into the tissue, (2) they can generate ROS in high quantum yield, and (3) they are nontoxic in the absence of light.^{2–4} Furthermore, researchers have developed efficient PDT-PSs by (a) preparing polymeric PS molecules for passive targeting based on the enhanced permeation retention (EPR) effect by the macromolecules often found in inflammatory diseases^{5–8} or by (b) adding disease-targeting

moieties to the PS cores to enhance the efficiency of PDT-PSs in an active manner via the selective delivery of the PS molecules to the specific tissues that need to be treated.^{9–12}


One of the current challenges in PDT research is to add imaging properties to the PSs to achieve image-guided PDT. By observing the *in vivo* biodistribution of the PS molecules in real time, it becomes possible to find the optimal timing for light irradiation for the most efficient treatment. For this purpose, bifunctional molecules with both photosensitizing and imaging properties have been reported. The majority of such molecules were made by connecting two types of functional moieties (PS cores and imaging probes) through the conjugation of these two parts.^{13–24} As an alternative approach, it is desirable to develop bifunctional molecules that can perform as both an imaging probe and a PDT-PS. In this study, we have chosen magnetic resonance imaging (MRI) as

Received: January 9, 2023

Revised: April 26, 2023

Accepted: April 28, 2023

Published: May 12, 2023






Figure 1. (a, b) Structures of pyridinyl porphyrin derivatives 1 (a) and 2 (b) and their Gd(III) complexes Gd-1 (a) and Gd-2 (b). (c) Structures of DOTA and GdDOTA.

an imaging modality and porphyrin as a PS core to design and synthesize water-soluble porphyrins with coordinated Gd(III) ion as bifunctional molecules for PDT-PSs and MRI-contrast agents (MRI-CAs). Only few studies on such bifunctional molecules have been reported.²⁵

MRI is highly relevant as a noninvasive *in vivo* imaging modality, since it provides in-depth high-resolution anatomical information on living bodies including small animals and humans without ionizing radiation. In the presence of MRI-CAs, enhanced image contrast can be obtained.²⁶ FDA-approved MRI-CAs are all paramagnetic Gd(III) chelates that

induce significant T_1 contrast enhancement and provide great benefits for 3D tomography visualization of tissues with high resolution (ca. 1 mm). Typical clinically used MRI-CAs consist of acyclic or cyclic poly(amino carboxylate) ligands, which strongly coordinate to the Gd(III) with 8-donor atoms (O or N) via Coulombic and dipole-cation interactions. For instance, the acyclic diethylenetriaminepentaacetate (DTPA) coordinates to Gd(III) through its three tertiary amines and five carboxylates and the macrocyclic tetraamine-cyclododecane tetraacetate (DOTA) complexes Gd(III) through four tertiary amines and four carboxylates (Figure 1c). In terms of

dissociation kinetics, macrocyclic chelates generally form more inert complexes with Gd(III) due to the higher preorganization of the ligand, which is appreciated as safer MRI-CAs by preventing the leakage of free toxic Gd³⁺ ions.²⁷ In these Gd(III) complexes, one coordination site of the metal is available for an inner sphere water molecule, which is essential in providing a good relaxation effect. The exchange of this coordinated water molecule with bulk water largely contributes to the relaxation enhancement observable in the MR images. The modulation of this coordinated water can be used to develop switchable contrast agents for the detection of specific biomarkers in the body.^{28,29}

We have chosen the porphyrin skeleton as a core for the ligand structures because it provides two functions: photosensitivity and Gd(III) complexation. Previously reported examples of MRI-CAs with porphyrin structures, such as the conjugates of porphyrin and Gd(III)-DOTA chelates, provided excellent relaxation enhancement and photoinduced ROS generation.^{13,23} On the other hand, molecules with a porphyrin as a ligand for Gd(III) complexation have been reported, but without assessment of their stability.^{30,31}

In the present study, two types of water-soluble pyridyl porphyrin derivatives **1** and **2** were designed as ligands for Gd(III), with substitution at the *meta* or *para* positions of the pyridyl group with carboxylate-terminated anchors (Figure 1a,b). We expected that these ligands would form Gd(III) complexes (**Gd-1** and **Gd-2**) through 8-coordination sites: four central nitrogen atoms of the porphyrin core and four oxygens of carboxylic acids in the termini of the anchors. Distinct from the stable metal complexation of porphyrins with smaller metal ions such as Fe(III) and Mg(II), which form a flat coordination environment in the porphyrin center, it is known that Gd(III), which has a relatively large ionic radius, only adopts a pyramidalized coordination mode in the porphyrin center with a sitting-atop form, often resulting in low complexation stability.³² To strengthen the Gd(III) coordination at the porphyrin center, anchor groups with a terminal carboxylic acid were added to the porphyrin core. Two porphyrins with 3-pyridyl substituent (compound **1**) and 4-pyridyl substituent (compound **2**) were designed as ligands for Gd(III) complexation (Figure 1). In addition to the terminal carboxylates, which were expected to stabilize the Gd(III) complexation of porphyrin ligands, it was expected that four cationic N-substituted pyridyl groups will provide water-solubility to the molecules. In the presence of an appropriate length of the alkyl chain (C₅ for **1** and C₇ for **2**) in the carboxylate anchors, relatively stable complexes **Gd-1** and **Gd-2** were obtained. Based on the stability test of these complexes, **Gd-1** showed sufficient stability in aqueous phase at neutral pH, while possessing significant *r*₁ relaxivity and photosensitivity, suggesting that this molecule may be a core of the MRI-PDT-theranostic drugs.

EXPERIMENTAL SECTION

Synthesis of **1**

To a solution of *N,N,N,N*-tetra(5-ethoxy-5-oxopentyl)-5,10,15,20-tetra(3-pyridyl)-21*H*,23*H*-porphyrin tetrabromide (**S2**) (180 mg, 0.124 mmol) in water (4 mL), a solution of LiOH monohydrate (156 mg, 3.72 mmol) in water (2 mL) was added. The reaction mixture was stirred at room temperature for 4 h until hydrolysis was completed as monitored by silica gel TLC (saturated KNO₃-H₂O-MeCN (1:1.5:8)). After the solvent was evaporated, crude mixture was dissolved in MeOH-MeCN (1:1), filtered, concentrated *in vacuo*,

and purified by reversed phase flash chromatography (C18 column with a gradient mixture of MeCN (0.1% TFA)-H₂O (0.1% TFA) (5:95 to 95:5) as an eluent). Product was triturated in 5 mL of Et₂O to provide a hygroscopic purple powder **1** (151 mg, 0.113 mmol, *y* = 91%); IR (ATR) ν_{\max} (cm⁻¹): 3320 (N-H), 3048 (C-H), 2933 (C-H), 1661 (C=O), 1503, 1405, 1169, 1110, 977, 912, 827, 797, 719, 692, 680; ¹H NMR (400 MHz, CD₃OD) δ_{H} 10.08 (4H, br s, *o*-py), 9.59 (4H, d, *J* = 6.2 Hz, *p*-py), 9.47 (4H, d, *J* = 8.0 Hz, *o*-py), 9.17 (8H, br s, β -pyrrole), 8.65 (4H, t, *J* = 7.0 Hz, *m*-py), 5.02–5.08 (8H, m, NCH₂CH₂CH₂CH₂), 2.49–2.59 (8H, m, NCH₂CH₂CH₂CH₂), 2.32–2.46 (8H, m, NCH₂CH₂CH₂CH₂), 1.85–1.96 (8H, m, NCH₂CH₂CH₂CH₂); ¹³C NMR (100 MHz, CD₃OD) δ_{C} 175.26, 148.58, 147.08, 144.63, 141.75, 138.46, 128.13, 126.80, 113.06, 61.91, 48.23, 32.48, 30.60, 21.12; HRMS (MALDI/ESI⁺) *m/z* calcd for [C₆₀H₆₃N₈O₈]⁺: 1023.4763, found: 1023.4755 ([M + H]⁺); UV-vis: λ_{\max} [nm] (ϵ [M⁻¹cm⁻¹]): 419 (236 000), 516 (13 000), 553 (2400), 584 (4700), 647 (628).

Synthesis of Gd-1

To a solution of compound **1** (15 mg, 0.011 mmol) in water (4 mL, adjusted to pH 6.3), Gd₂O₃ (425 mg, 1.17 mmol) was added. The reaction mixture was refluxed for 68 h at pH 6.3. The reaction process was monitored by UV-vis spectroscopy. After completion of the reaction, the reaction mixture was cooled to room temperature and filtered through a syringe filter (0.45 μ m) to remove excess Gd₂O₃. Subsequently, the pH was adjusted to 9.0 to precipitate Gd(OH)₃, which was filtered off (0.45 μ m syringe filter). The pH of the solution was adjusted to 7.0 and filtered and the filtrate was concentrated *in vacuo*. The obtained crude mixture was purified by SEC (Sephacore CL-4B) with an eluent of Milli-Q water to remove a trace amount of starting material and then Milli-Q water containing 0.1% Et₃N to elute the product. Product was triturated with Et₂O to provide a hygroscopic bright red powder **Gd-1** (13.1 mg, 0.0105 mmol, *y* = 93%); IR (ATR) ν_{\max} [cm⁻¹]: 3094 (C-H), 2959 (C-H), 1677 (C=O), 1565, 1422, 1353, 1193, 1177, 1125, 1104, 960, 836, 798, 720, 680, 519; HRMS (ESI⁺) *m/z* calcd for [C₆₀H₅₇Gd₁N₈O₈]²⁺: 587.6765, found: 587.6778 ([M + H]²⁺); UV-vis: λ_{\max} [nm] (ϵ [M⁻¹cm⁻¹]): 429 (184 000), 517 (3700), 556 (11 300), 588 (2700).

Synthesis of **2**

To a solution of **S4** (33 mg, 0.021 mmol) in water (2 mL), a solution of LiOH monohydrate (26.5 mg, 0.63 mmol) in water (1 mL) was added. The reaction mixture was stirred at room temperature, and the reaction was monitored by a silica gel TLC (saturated KNO₃-H₂O-MeCN (1:1.5:8)) to observe the completion of hydrolysis after 4 h. After the solvent was evaporated, the crude mixture was dissolved in a mixture of MeOH and MeCN (1:1) and filtered, and solvents were concentrated *in vacuo*. The crude mixture was purified by reverse phase chromatography in the same manner as for **1** above. The product was triturated in 5 mL of Et₂O to provide a hygroscopic purple powder **2** (26.5 mg, 0.018 mmol, *y* = 86%); IR (ATR) ν_{\max} [cm⁻¹]: 3317 (N-H), 3052 (C-H), 2936 (C-H), 2864, 1672 (C=O), 1636 (C=O), 1562 (C-N), 1511, 1458, 1404, 1198, 1174, 1128, 970, 799, 719; ¹H NMR (400 MHz, CD₃OD): δ_{H} 9.50 (8H, dd, *J* = 6.5 and 3.7 Hz, *o*-py), 9.16 (8H, brs, β -pyrrole), 9.02 (8H, d, *J* = 6.5 Hz, *m*-py), 5.04 (8H, t, *J* = 7.7 Hz, NCH₂), 2.36–2.51 (16H, m, NCH₂CH₂CH₂CH₂CH₂CH₂CH₂), 1.61–1.86 (24H, m, NCH₂CH₂CH₂CH₂CH₂CH₂); ¹³C NMR (100 MHz, CD₃OD) δ_{C} 176.11, 158.38, 158.13, 143.26, 143.20, 143.17, 132.98, 129.85, 129.73, 115.67, 115.23, 61.81, 33.29, 31.10, 28.25, 25.73, 24.35; HRMS (MALDI/ESI⁺) *m/z* calcd for [C₆₈H₇₉N₈O₈]⁺: 1135.6015, found: 1135.6013 ([M + H]⁺); UV-vis: λ_{\max} [nm] (ϵ [M⁻¹cm⁻¹]): 425 (131 000), 520 (11 000), 558 (5300), 586 (5300), 641 (2086).

Synthesis of Gd-2

To a solution of compound **2** (14 mg, 0.0097 mmol) in water (7 mL, adjusted to pH 6.3), Gd₂O₃ (280 mg, 0.77 mmol) was added, and the reaction mixture was refluxed for 96 h at pH 6.3. The reaction process was monitored by UV-vis spectroscopy. After completion of the reaction, the mixture was cooled to room temperature and filtered through a syringe filter (0.45 μ m) to remove excess Gd₂O₃. A further




Figure 2. UV-vis spectra of porphyrin ligands **1** and **2** and their corresponding Gd(III) complexes **Gd-1** and **Gd-2** in HEPES buffer (pH 7.4) at 12.5 μM .

purification process was performed in the same manner as **Gd-1** above to provide a hygroscopic brown powder **Gd-2** (2.8 mg, 0.0021 mmol, $y = 21\%$); IR (ATR) ν_{max} [cm^{-1}]: 3119, 3052 (C–H), 2938 (C–H), 2863, 1675 (C=O), 1634 (C=O), 1558 (C–N), 1409, 1201, 1173, 1123, 999, 836, 799, 720; HRMS (ESI⁺) m/z calcd for $[\text{C}_{68}\text{H}_{74}\text{Gd}_1\text{N}_8\text{O}_8]^{3+}$: 429.4957, found: 429.4957 ($[\text{M} + 2\text{H}]^{3+}$); UV-vis: λ_{max} [nm] (ϵ [$\text{M}^{-1}\text{cm}^{-1}$]): 436 (162 000), 525 (3500), 561 (13 500).

ICP-OES Measurement

ICP-OES measurements were performed to quantify the Gd content and to gain information concerning the stoichiometry of the complex. An aqueous solution of **Gd-1** was diluted and digested in 2% HNO_3 solution prior to the ICP-OES analysis. As standard, a 1000 ppm solution of Gd(III) in 2% HNO_3 was diluted to 50–2000 ppb and used for the calibration. Measurements were performed on an Ultima Expert ICP-OES (Horiba Ltd., Kyoto, Japan).

Relaxometric Measurements

¹H NMRD (nuclear magnetic relaxation dispersion) profiles of aqueous 1.97 mM **Gd-1** solution (pH = 7.0) were measured at 25 and 37 °C on a Stellar SMARtracer Fast Field Cycling NMR relaxometer (0.00024–0.24 T, 0.01–10 MHz ¹H Larmor frequency) (Stellar s.r.l, Mede, Italy) and a Bruker WP80 NMR electromagnet adapted to variable-field measurements (0.47–1.88 T, 20–80 MHz) and controlled by the SMARtracer PC-NMR console. The temperature was controlled by a VTC91 temperature control unit and maintained by a gas flow. The temperature was determined according to previous calibration with a Pt resistance temperature probe. The Gd³⁺ concentration of the sample was verified by ICP-OES measurement. The relaxivity at 400 MHz was determined on a Bruker Advanced NMR spectrometer.

¹⁷O NMR Studies

Variable-temperature ¹⁷O NMR measurements of an aqueous solution of **Gd-1** were performed on a Bruker Advanced 400 MHz spectrometer using a 10 mm BBFO probe (9.4 T, 54.2 MHz) in the temperature range of 5–75 °C. The temperature was calculated according to published calibration routines with ethylene glycol and MeOH. Acidified water (HClO_4 , pH 3.3) was used as a diamagnetic reference. Transverse ¹⁷O relaxation times were obtained by the Carlschell-Meiboom-Gill spin-echo technique, and longitudinal relaxation rates were measured by an inversion recovery method. To eliminate susceptibility corrections to the chemical shifts, the sample was placed in a glass sphere fixed in a 10 mm NMR tube. To improve sensitivity, H₂¹⁷O (10% H₂¹⁷O, CortecNet) was added to achieve ~1% ¹⁷O content in the sample. The pH of the sample was 7.0, and the **Gd-1** complex concentration was 6.75 mmol·kg⁻¹.

DNA Cleavage Assay

The supercoiled pBR322 DNA (New England Biolabs) was used as a substrate. A mixture of pBR322 DNA (12.5 $\mu\text{g}\cdot\text{mL}^{-1}$) and **Gd-1** (0.1 mM) in 10 mM Tris-HCl (pH 8.0) was placed in the 96-well micro plate and irradiated with a green LED light (dominate wavelength: 527 nm, 25 mW per well) using a Lumidox Gen II Apparatus (Analytical Sales & Services, Inc., Franders, NJ, USA). Each sample was mixed with Gel Loading Dye Purple (New England Biolabs, Inc.) and subjected to the agarose gel electrophoresis. Subsequently, the gel was stained with GelRed Nucleic Acid Gel Stain (Biotium, Inc., Fremont, California, USA) and visualized and photographed using a ChemiDoc MP transilluminator (Bio-Rad Laboratories, Inc., Hercules, California, USA). The photographed images were analyzed using ImageJ³³ to quantify the relative amount of intact DNA (*Form I*) and nicked circular DNA (*Form II*).

ESR Spin-Trapping Method for the Detection of ¹O₂

The generation of ¹O₂ was detected by an ESR method using 4-oxo-TEMP as a spin-trapping reagent. Rose Bengal was used as a standard ¹O₂ generator. To a 20 μL solution of each porphyrin (0.5 mM in D₂O), 4 μL of 4-oxoTEMP (0.5 M in D₂O), 10 μL of phosphate buffer (pH 7, 0.3 M in D₂O), and D₂O (16 μL) were added and mixed well under an aerobic condition. Each mixture was irradiated by green LED light at a distance of 3 cm for 0, 1, 2, 5, and 10 min and immediately subjected to ESR measurement. The generation of ¹O₂ was detected by an ESR signal of 4-oxo-TEMPO, formed by the reaction of ¹O₂ and 4-oxo-TEMP.

Photocytotoxicity Assay

After preincubation for 24 h, cells (U2OS, HeLa, UMUC-3, and HCT116) were exposed to the chemicals (**Gd-1**: 10 or 40 μM , **Gd-2**: 10 μM , or TMPyP4:10 μM) solubilized in culture medium (100 μL) for 24 h. Subsequently, the cells were washed twice with PBS(–) and were exposed to green LED using Lumidox II illuminator (527 nm, 95 mW per well, Analytical Sales and Services, Inc.) for 0 to 30 min. Cells were incubated in fresh medium for an additional 24 h, and cell viability was tested by the MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega).

RESULTS AND DISCUSSION

Design and Synthesis of Ligands **1** and **2** and Their Gd(III) Complexes (**Gd-1** and **Gd-2**)

The lengths of alkyl anchors with carboxylate termini in the porphyrin-based ligands **1** and **2** were selected with the aid of molecular modeling to afford the highest complexation stability

in the corresponding Gd(III) chelates **Gd-1** and **Gd-2** (Table S1, Section 1 in the SI).^{34,35} Compounds **1** and **2** were synthesized from tetrapyrridylporphyrins (**S1** and **S3**) as starting materials. The N atoms of **S1** or **S3** at *meta* or *para* position were alkylated by the corresponding bromide with terminal ethyl ester to provide **S2** or **S4** (Schemes S1 and S2, Section 2 in the SI). After subsequent deprotection of the terminal carboxylates by LiOH, ligands **1** and **2** were obtained and purified by reversed phase HPLC. The final Gd(III)-chelation step was performed by refluxing the ligand **1** or **2** in the presence of an excess amount of Gd₂O₃ in aqueous solution (pH 6.3) for 3 or 5 days. After the reaction completed, the remaining free Gd³⁺ was removed as precipitates of Gd(OH)₃ at pH 9 together with excess Gd₂O₃ precipitates. The resulting Gd(III) complexes **Gd-1** and **Gd-2** were further purified by Sepharose CL-4B size exclusion chromatography (SEC) using water (in the presence of 0.1% Et₃N) as an eluent. The obtained fractions corresponding to complexes **Gd-1** and **Gd-2** were collected and analyzed by HR-ESI-MS (Figure S11 and S24 in the SI), which provided molecular ion peaks, respectively, at [M + H]²⁺ for **Gd-1** and [M+2H]³⁺ for **Gd-2**, indicating that both complexes contained 1 atom of Gd³⁺ per porphyrin ligand molecule (**1** or **2**). It was also confirmed that there was no peak corresponding to free porphyrin ligand (**1** or **2**) nor to other complexes with multiple numbers of Gd³⁺ atoms per ligand observed in the ESI-MS spectra. The results indicated that the fraction obtained by SEC purification was sufficiently pure without containing any free ligand or different mode of Gd(III) complexes (e.g., 1 to 2 complexation of Gd³⁺ and porphyrin ligands). The one-to-one complexation mode of **Gd-1** was also confirmed by ICP-OES for the quantification of Gd amount to further indicate that the purity of the complex was >99% (for details, see Section 3 in the SI).

Figure 2 shows normalized UV–vis absorption spectra of free ligands (**1** and **2**) and their complexes (**Gd-1** and **Gd-2**). Upon Gd(III) complexation, clear changes in Q-bands were observed in both **Gd-1** and **Gd-2**. Changes in the four Q-bands of **1** (516, 553, 584, and 647 nm) and **2** (520, 558, 586, and 641 nm) to the ones for Gd(III) chelates (**Gd-1**: 517, 556, and 588 nm; **Gd-2**: 525 and 561 nm) indicated that the metal complexation with ligands **1** and **2** involved coordination via the pyrrolic nitrogen atoms at the porphyrin center. In addition, the observed red shift of the Soret bands (from 419 to 429 nm and from 425 to 436 nm, respectively, for **Gd-1** and **Gd-2**) suggested that the metalation proceeded with a sitting atop (SAT) structure.^{36,37} The complexation was also investigated by FT-IR-ATR measurements in the solid state (Figure S25). The bands corresponding to the N–H stretches, observed in free ligands **1** and **2** at 3320 and 978 or at 3317 and 980 cm⁻¹, respectively (Figure S25a,c), were not observed in complexes **Gd-1** and **Gd-2** (Figure S25b,d). This further indicates that the metal was coordinated to the porphyrin core through the central N atoms. Simultaneously, two additional peaks were observed upon complexation at ca. 1560–1565 and 1410–1420 cm⁻¹, presumably related to Gd(III) complexation by the terminal carboxylic acid groups of the anchors connected to the pyridyl nitrogen atoms. In comparison to **1** and **Gd-1**, the spectra of **2** and **Gd-2** were much broader, presumably related to the increased aggregation of **2** and **Gd-2**. This may be due to the geometrically favorable cation– π interaction of the *para* position that is observed for other water-soluble porphyrins with cations at the *para* position.

Stability of **Gd-1** and **Gd-2**

During the purification step of each complex by SEC, **Gd-2** was obtained in rather low yield (21%), presumably due to partial decomplexation during chromatography. In contrast, **Gd-1** was obtained with an excellent yield (93%), probably due to its higher stability in comparison to **Gd-2**. There was a clear difference in the stability of **Gd-1** and **Gd-2** in pH 5.5 phosphate buffer; while complex **Gd-2** was immediately decomplexed (data not shown), complex **Gd-1** was stable in the same buffer for at least 1 h as observed by UV–vis spectra.

The stability of complex **Gd-1** in aqueous solution was assessed in more detail by UV vis measurements (Figures S26–S35). While **Gd-1** was stable in pH 5.5 phosphate buffer for a short interval (1 h), decomplexation of **Gd-1** was prevalent after 24 h (Figure S26a). The further stability tests of **Gd-1** at higher pH showed, however, that this complex was stable at pH 6.8, 7.4, and 9.4 (in HEPES buffer) at least for 168 h (Figure S26b–d). In the experiments in phosphate buffer at pH 6.0, 6.4, 6.6, and 6.8 and in citrate buffer at pH 6.5 and 6.8, the spectral changes corresponding to the partial decomplexation were observed below pH 6.5, indicating that the complex **Gd-1** was sufficiently stable at pH 6.8 or higher (Figures S27–28). The repeated thermal hysteresis (repeated cycles of 50 and 4 °C for 30 min each) did not cause any decomplexation of **Gd-1** (Figure S29). We found that decomplexation of **Gd-1** took place at pH 7.0 in the presence of one equivalent of Zn(II) or complexing agent EDTA, which were observed as a drop of relaxivity at 60 MHz (Figure S37). The addition of a large excess of sodium citrate tribasic and other competing metal ions such as Ca(II) and Mg(II) did not affect the stability of **Gd-1** (Figures S30–S33). Storing at higher concentration (45 mM) at 4 °C in phosphate buffered saline (PBS, pH 7.4) did not cause any significant decomplexation or increased aggregation of **Gd-1** at least for 72 h (Figure S34). Further, we have confirmed that **Gd-1** was stable at pH 7.0 under visible light irradiation conditions (528 nm) in the presence of oxygen (Figure S35).

Relaxivity Measurements of **Gd-1**

Based on the sufficient stability shown above, the paramagnetic relaxation enhancement properties of **Gd-1** were evaluated by relaxivity measurements at variable magnetic fields (0.01–400 MHz) and at two temperatures (25 and 37 °C, Figure 3). Proton relaxivity is defined as the paramagnetic enhancement of the water proton relaxation rate referred to 1 mM Gd(III) concentration, and it directly translates to MRI efficiency. Relaxivity is dependent on a large number of parameters, the most important being the number of water molecules directly coordinated to the metal ion (hydration number, q), the exchange rate of this water with the bulk (k_{ex}), and the rotational correlation time of the complex (τ_R). The relaxivity values are remarkably high for **Gd-1**; at 20 MHz and 37 °C, r_1 is about four times higher than that of typical small molecular weight complexes such as the clinical agent GdDOTA (Table 1). The shape of the NMRD profiles, with a bump centered at ~60 MHz, qualitatively indicates that rotation is slower than expected for a small molecular weight complex. This is likely a consequence of an aggregation phenomenon in the solution, which is commonly observed even for water-soluble porphyrins. Indeed, the same observation was previously reported for porphyrins decorated with Gd(III) complexes.^{13,22–24}

For a better analysis of the relaxivities, the NMRD (Nuclear Magnetic Relaxation Dispersion) data have been comple-




Figure 3. (a) Transverse (red \blacklozenge) and longitudinal (blue \blacktriangle) ^{17}O reduced relaxation rates and (b) reduced ^{17}O chemical shifts measured in a Gd-1 solution at 6.75 mM, pH 7. (c) ^1H NMRD profiles of the Gd-1 complex (1.97 mM in 0.1 M HEPES (pH 7.3)) recorded at 37 °C (green \bullet) and at 25 °C (black \bullet). The lines correspond to the fit as explained in the text.

mented by a variable temperature ^{17}O NMR study that allowed the direct assessment of the water exchange and the rotational dynamics of Gd-1, two features directly interfering in the relaxation efficiency of paramagnetic metal chelates. Indeed, the transverse ^{17}O relaxation rates contain information on the water exchange process, while longitudinal ^{17}O relaxation is related to the rotational dynamics of the complex. The reduced transverse ($1/T_{2r}$) and longitudinal ($1/T_{1r}$) ^{17}O relaxation rates have been determined for an aqueous solution of Gd-1 (6.75 mM, pH 7). The temperature dependency of $1/T_{2r}$ indicates that above ~ 298 K the system is in the fast exchange

Table 1. Experimental Relaxivities, r_1 , and Calculated Parameters Characterizing the Water Exchange and the Rotational Dynamics of Gd-1 in an Aggregated State and the Small Molecular Weight Reference Compound GdDOTA

	Gd-1 ^a	GdDOTA ^b
r_1 (20 MHz, 37 °C) [$\text{mM}^{-1} \text{s}^{-1}$]	15.46	3.83
k_{ex}^{298} [s^{-1}]	$(8.1 \pm 0.5) \times 10^6$	4.1×10^6
ΔH^\ddagger [kJ/mol]	27.5 ± 0.5	49.8
τ_R [ps]	850 ± 35 (from NMRD)	77
	930 ± 28 (from ^{17}O NMR)	
$E_R/\text{kJ/mol}$	28.1 ± 0.5	16.1

^aThis work. ^bRef 38.

regime, while at lower temperatures, it is in the slow exchange regime. The ^{17}O NMR and the NMRD data have been analyzed together by using the Solomon-Bloembergen-Morgan theory of paramagnetic nuclear relaxation²⁴ to obtain the characteristic parameters for the description of the water exchange process (k_{ex}^{298} and the activation enthalpy ΔH^\ddagger) and the rotational dynamics (τ_R^{298} and the activation energy E_R), which are listed in Table 1, together with the corresponding values for GdDOTA. Only the high field relaxivities (>4 MHz) have been included in the analysis. It is common to fit only the high field part of the NMRD profile, as at low magnetic fields, the SBM theory fails in describing electronic parameters and rotational dynamics of slowly rotating objects. In the fit, we assumed one inner sphere water molecule, in accordance with the expected coordination of four porphyrin nitrogens and four carboxylates to the metal ion. The value of the scalar coupling constant calculated is $A/\hbar = -3.4$ MHz, which is in the usual range for Gd(III) chelates, suggesting that the assumption of one inner sphere water is correct. A complete description of the analysis, including the equations used for the fitting of the experimental ^{17}O and NMRD data as well as the full set of the fitted parameters, can be found in the SI.

The water exchange rate, k_{ex}^{298} , is double of that for GdDOTA, but this difference will not affect the relaxivity since it is still limited by rotation. The most important information on this analysis concerns the slow rotational dynamics, confirmed by the value of the rotational correlation time, $\tau_R^{298} = 850$ ps. Slow rotation is also indicated by the longitudinal ^{17}O relaxation rates. These were acquired at a higher concentration (6.75 mM) than the NMRD data (1.97 mM), and they indeed provide a slightly longer rotational correlation time, $\tau_R^{298} = 930$ ps. We also recorded the relaxivity of Gd-1 at variable concentrations between 0.1 and 6.4 mM and found an important concentration dependency, consistent with aggregation (Figure 4), which was observed also by DLS measurement (Figure S36). Even in the most diluted samples (down to 0.02 mM concentration), the relaxivity continues to decrease with decreasing concentration, suggesting that aggregation is still present. The measurement of relaxivities at lower concentration becomes technically problematic; therefore, we cannot characterize the monomer state. In any case, the slower rotation is responsible for the high relaxivity of the complex. Further, the transverse relaxivity, r_2 , was measured at two Gd-1 concentrations, at 60 MHz and 25 °C. The values are the following: $r_2 = 27.0 \text{ mM}^{-1} \text{ s}^{-1}$ and $r_1 = 21.4 \text{ mM}^{-1} \text{ s}^{-1}$ at 4.8 mM and $r_2 = 23.9 \text{ mM}^{-1} \text{ s}^{-1}$ and $r_1 = 19.4 \text{ mM}^{-1} \text{ s}^{-1}$ at 2.4 mM concentration.




Figure 4. Concentration-dependent relaxivity change of Gd-1 (60 MHz, 298 K).

Photo DNA Cleavage by Gd-1

For the preliminary evaluation of complex Gd-1 as a PS, photoinduced DNA-cleaving tests were performed under visible light irradiation. A standard assay method using pBR322 supercoiled plasmid DNA was used to evaluate the oxidative damage of DNA by photoexcited Gd-1. A green LED (dominate wavelength: 527 nm, 25 W per well) was used as a light source, where Gd-1 has an absorption intensity. As a result, significant DNA cleavage by Gd-1 was observed in an irradiation-time-dependent manner (lanes 3 and 4, Figure 5). No significant DNA cleavage was observed in the absence of light (lane 2) or Gd-1 (lanes 5 and 6) clearly indicating that photoexcitation of Gd-1 was necessary to cleave DNA.




Figure 5. Photoinduced DNA cleavage by Gd-1. DNA used in the assay: pBR322 supercoiled DNA (0.125 μg ; 6.25 $\mu\text{g}\cdot\text{mL}^{-1}$); Gd-1: 0.1 mM in 15 mM Tris-HCl buffer (pH 8.0); light irradiation: green-LED (527 nm, 25 W per well) for 5 min (+) or 10 min (++) . Form I: intact DNA. Form II: nicked DNA.

ROS Generation by Gd-1 under Photoirradiation

From the DNA cleavage test above, it was expected that reactive oxygen species (ROS), especially singlet oxygen ($^1\text{O}_2$) generated by *type II* energy transfer reaction, may act as a key active species to cause the DNA cleavage by the photosensitizers.^{1,39–41} To confirm this mechanism in the photoinduced DNA cleavage by Gd-1, the ESR spin-trapping methods were employed to detect the ROS generation under

irradiation of green LED lights (dominate wavelength: 528 nm; luminous flux: 9 lm).

The generation of $^1\text{O}_2$ was evaluated by ESR using 4-oxo-TEMP as a spin-trapping reagent (Figure 6e).⁴² The complex




Figure 6. (a–d) X-band ESR spectra for $^1\text{O}_2$ adduct of 4-oxo-TEMP (4-oxo-TEMPO) generated from Gd-1 (a), 1 (b), Gd-2 (c), and 2 (d) under photoirradiation. Reaction conditions: Gd-1, 1, Gd-2, or 2: 0.2 mM; 4-oxo-TEMP: 40 mM; in 60 mM phosphate buffer (pH 7, in D_2O); light irradiation: green-LED (dominate wavelength: 528 nm; luminous flux: 9 lm) for 10 min. Measurement conditions: temperature 296 K, microwave frequency 9.375 GHz, microwave power 1 mW, modulation amplitude 4.00 G, modulation frequency 100 kHz, scan time 20.5 s. (e) General scheme for the photoinduced DNA cleavage by a photosensitizer (S).

Gd-2 and free ligands 1 and 2 were also tested for $^1\text{O}_2$ generation. Upon green light irradiation, the specific ESR signals corresponding to 4-oxo-TEMPO, the $^1\text{O}_2$ adduct of 4-oxo-TEMP, were observed in aqueous solutions of Gd-1 (Figure 6a). The amount of $^1\text{O}_2$ generation in Gd-1 was higher than in Gd-2 (Figure 6c) and greater than a positive control Rose Bengal, a well-known $^1\text{O}_2$ generator (Figure S38). Interestingly both free ligands 1 and 2 showed higher generation of $^1\text{O}_2$ than their corresponding complexes (Figures 6, S38, and S39) presumably due to higher absorption intensity at 527 nm (Figure 2).

Cytotoxicity

As a preliminary test on the biocompatibility of Gd-1, a cytotoxicity assay was performed. The effects of these complexes on cell growth and cell cycle progression were examined on three types of cancer cell lines: HCT116 (colorectal carcinoma), U2OS (osteosarcoma), and UMUC-3 (bladder carcinoma) by monitoring the increase of the cell numbers (Figure S40). As reference compounds, Gd-2 and tetra *N*-methyl pyridyl porphyrin (TMPyP4) were used. As results, Gd-1 did not show any effect on cell growth of any tested cell line at the concentration of 1 μM (Figure S40). No effect was observed in UMUC-3 at the concentration of 10




Figure 7. Effects of light irradiation on the growth of four types of cancer cells treated with **Gd-1**, **Gd-2**, and **TMPyP4**. Cells (U2OS (a), HeLa (b), UMUC-3 (c), and HCT116 (d)), preincubated with **Gd-1** (10 or 40 μM) or **Gd-2** (10 μM), were exposed to the green LED light (528 nm, 95 mW per well) for 0, 5, 10, 15, and 30 min and subjected to the MTS assay for measuring the viability. As controls, cells were treated in the absence of drug (no drug) or in the presence of **TMPyP4** (10 μM). Values are means \pm SD ($n = 4$). Gray, **Gd-1** (10 μM); yellow, **Gd-1** (40 μM); orange, **Gd-2** (10 μM); light blue, **TMPyP4** (10 μM); blue, no drug (negative control).

μM , while **Gd-1** slightly retarded the cell growth in HCT116 and U2OS. The growth inhibitory effect was smaller than the control experiment with **TMPyP4** in UMUC-3 but was bigger than the control **TMPyP4** in HCT116 and U2OS. It was technically difficult to estimate the effect of **Gd-1** on the cell growth above 10 μM due to its high fluorescent intensity. Interestingly, the **Gd-2** complex with lower stability did not show any significant effect on cell growth at the concentrations up to 50 μM in all the cell lines. The effect of **TMPyP4** may be related to its function to intercalate into guanine quadruplexes (G4) that may inhibit ongoing DNA replication or could alter the expression of oncogenes known to be regulated by G4 in cancer cells. Similarly, the effect of **Gd-1** may also be related to its G4 binding.⁴³ Moreover, taken together with the fact that **Gd-1** generated $^1\text{O}_2$ much more efficiently than **Gd-2** under visible light irradiation (Figure 5), the cell growth inhibition by **Gd-1** may be also related to the effect of light, as cells were exposed to traces of light, which could not be avoided during the experimental procedure.

Effect to Cell Cycle Progression

To obtain further insight into the effect of **Gd-1** on the cells, the impact on the cell cycle progression was examined by analyzing the DNA contents in U2OS and HeLa (human cervical adenocarcinoma) cells, both of which are commonly used for detection of changes in cell cycle progression (Figure S41).^{44,45} Cell cycle distributions did not significantly change in the presence of both **Gd-1** (10 μM) and **Gd-2** (5 μM) in either cell line, indicating that there were little inhibitory effects on DNA replication and on mitotic events by these Gd(III) complexes.

Photocytotoxicity

Finally, photocytotoxicity of **Gd-1** was investigated using green LED light on four types of cancer cell lines (U2OS, HeLa, UMU-3, and HCT116). As references, **TMPyP4** and **Gd-2** were tested. As shown in Figure 7, in all cell lines, both **Gd-1** and **Gd-2** exhibited significant photocytotoxicity dependent on the time of light irradiation. Among them, **Gd-1** showed stronger photocytotoxicity than **Gd-2**, in line with the results that **Gd-1** has a higher ability of $^1\text{O}_2$ generation as shown in Figure 5. **Gd-1** exhibited photocytotoxicity almost identical with that shown by the control compound **TMPyP4**, most notably on U2OS, UMU-3, and HCT116. Taking into account that **Gd-1** showed low cytotoxicity in the absence of light, it was suggested that **Gd-1** can be a good candidate as a core for the PDT-PS molecule.

CONCLUSIONS

Two water-soluble porphyrin-based Gd(III) chelates, **Gd-1** and **Gd-2**, were synthesized. The introduction of carboxylate anchors increased the stability of Gd(III)–porphyrins complexes, especially in the case of **Gd-1**. The ^1H NMRD study of **Gd-1** showed high r_1 relaxivities indicating that **Gd-1** has good relaxation efficacy, which is related to the aggregation of the compound in aqueous solution. The complex **Gd-1** revealed extensive photoinduced DNA cleavage and $^1\text{O}_2$ generation, suggesting that it can be a potential candidate as a PDT-PS drug. Significant cytotoxicity was not observed with **Gd-1** in the dark, while clear photocytotoxicity was shown under visible light irradiation. Overall, the **Gd-1** complex combines good r_1 relaxivity and efficient ROS generation with

corresponding photocytotoxicity, important for theranostic drugs for MR image-guided PDT.

■ ASSOCIATED CONTENT

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/cbmi.3c00007>.

Additional experimental details on synthesis of Gd-1 and Gd-2 with spectroscopic data including their intermediates; stability test, ICP-OEC analysis, and relaxivity measurements with corresponding equations for Gd-1; photoinduced DNA cleavage test and ROS generation, detailed cell assay tests, and photocytotoxicity for Gd-1 and Gd-2 (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Hisao Masai – Department of Basic Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo 156-8506, Japan; orcid.org/0000-0003-1268-5302; Email: masai-hs@igakuken.or.jp

Yoko Yamakoshi – Department of Chemistry and Applied Biosciences, ETH Zürich, CH8093 Zürich, Switzerland; orcid.org/0000-0001-8466-0118; Email: yamakoshi@org.chem.ethz.ch

Éva Tóth – Centre de Biophysique Moléculaire, CNRS UPR 4301, University of Orléans, 45071 Cedex 2 Orléans, France; Email: eva.jakabtoth@cnrs.fr

Authors

Tamas Nemeth – Department of Chemistry and Applied Biosciences, ETH Zürich, CH8093 Zürich, Switzerland; orcid.org/0000-0003-4739-5882

Naoko Yoshizawa-Sugata – Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo 156-8506, Japan; orcid.org/0000-0001-8792-8669

Agnes Pallier – Centre de Biophysique Moléculaire, CNRS UPR 4301, University of Orléans, 45071 Cedex 2 Orléans, France

Youichi Tajima – Department of Basic Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo 156-8506, Japan; orcid.org/0000-0002-9597-7054

Yue Ma – Department of Chemistry and Applied Biosciences, ETH Zürich, CH8093 Zürich, Switzerland; orcid.org/0000-0002-6476-3715

Complete contact information is available at: <https://pubs.acs.org/10.1021/cbmi.3c00007>

Author Contributions

N.Y.-S., H.M., and Y.Y. initiated and designed the overall project. T.N. designed the detailed structure of the molecules and carried out the synthesis and characterization of the molecules (^1H and ^{13}C NMR, IR, UV, TOF-MS, ICP-OES, stability test, and ROS generation), and Y.M. performed the characterization of **Gd-1** (HR-ESI-MS, DLS, photostability, and photo DNA cleavage) in collaboration with E.T., H.M., and Y.Y. E.T. and A.P. carried out the detailed characterization on the relaxivity of the Gd(III) complexes. Y.T. and N.Y.-S. performed the cell assays for the biocompatibility and

photocytotoxicity of the Gd(III) complexes in collaboration with H.M.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank Dr. Rubi of the MoBiAS in the Department of Chemistry and Applied Biosciences at the ETH Zürich for his support in HR-MALDI-TOF measurements. The authors thank Dr. Liosi and Dr. Fracassi from the ETH Zürich for their help in ESR measurements and relaxivity evaluation. The authors thank Ms. Naoko Kakusho from Tokyo Metropolitan Institute of Medical Sciences for conducting FACS cell cycle analyses of cancer cells. The authors thank Prof. Helm in EPFL for his educational discussion. This research was supported in part by the SNF, Strategic Japanese-Swiss Science and Technology Program (IZLJZ2_183660, Y.Y.), JSPS under the Joint Research Program implemented in association with SNF (20191508, H.M. and N.Y.-S.), the SNF Project Funding (205321_173018, Y.Y.), the ETH Research Grant (ETH-21_15-2; ETH-36_20-2, Y.Y.), and JSPS KAKENHI (Grant-in-Aid for Scientific Research [A], 6251004, H.M.; Grants-in-Aid for Scientific Research on Innovative Areas, 21H00264, 22H04707, H.M.; Grant-in-Aid for Scientific Research [C], 15K07164, N.Y.-S.).

■ ABBREVIATIONS

LED, light emitting diode; NADH, nicotine amide adenine dinucleotide; PDT, photodynamic therapy; PS, photosensitizer; FDA, US Food and Drug Administration; ROS, reactive oxygen species; MRI, magnetic resonance imaging; CA, contrast agent; DTPA, 2,2',2'',2'''-[[[(carboxymethyl)-azanediy]bis(ethane-2,1-diyl)nitro]} tetraacetic acid; DOTA, 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)-tetraacetic acid; HR-MALDI-MS, high resolution-matrix assisted laser desorption/ionization mass spectrometry; ICP-OES, inductively coupled plasma-optical emission spectrometry; SAT, sitting atop; UV-vis, ultraviolet-visible spectroscopy; DNA, deoxyribonucleic acid; ESR, electron spin resonance spectroscopy; 4-oxo-TEMP, 2,2,6,6-tetramethyl-4-piperidone; 4-oxo-TEMPO, 4-oxo-2,2,6,6-tetramethyl-1-piperidinyloxy; DMPO, 5,5-dimethyl-1-pyrroline N-oxide; DETAPAC, diethylenetriaminepentaacetic acid; SEC, size exclusion chromatography; NMRD, nuclear magnetic relaxation dispersion; HEPES, diethylenetriaminepentaacetic acid; TMPyP4, meso-5,10,15,20-tetrakis(*N*-methyl-4-pyridyl) porphyrin; G4, guanine quadruplex

■ REFERENCES

- (1) Baskaran, R.; Lee, J.; Yang, S. G. Clinical Development of Photodynamic Agents and Therapeutic Applications. *Biomater. Res.* **2018**, *22*, 25.
- (2) Dabrowski, J. M.; Arnaut, L. G. Photodynamic Therapy (PDT) of Cancer: From Local to Systemic Treatment. *Photochem. Photobiol. Sci.* **2015**, *14* (10), 1765–1780.
- (3) Bolze, F.; Jenni, S.; Sour, A.; Heitz, V. Molecular Photosensitizers for Two-Photon Photodynamic Therapy. *Chem. Commun.* **2017**, *53* (96), 12857–12877.
- (4) Yamakoshi, Y. Potential of Fullerenes for Photodynamic Therapy Application. In *Handbook of Fullerene Science and Technology*; Lu, X., Akasaka, T., Slanina, Z., Eds.; Springer: Singapore, 2021; DOI: 10.1007/978-981-13-3242-5_39-1.

- (5) Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer-Chemotherapy - Mechanism of Tumorotropic Accumulation of Proteins and the Antitumor Agent Smancs. *Cancer Res.* **1986**, *46* (12), 6387–6392.
- (6) Fox, M. E.; Szoka, F. C.; Frechet, J. M. J. Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture. *Acc. Chem. Res.* **2009**, *42* (8), 1141–1151.
- (7) Haag, R.; Kratz, F. Polymer Therapeutics: Concepts and Applications. *Angew. Chem.-Int. Ed.* **2006**, *45* (8), 1198–1215.
- (8) Maeda, H. Macromolecular therapeutics in cancer treatment: The EPR Effect and Beyond. *J. Controlled Release* **2012**, *164* (2), 138–144.
- (9) Chari, R. V. J.; Miller, M. L.; Widdison, W. C. Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy. *Angew. Chem.-Int. Ed.* **2014**, *53* (15), 3796–3827.
- (10) Casi, G.; Neri, D. Antibody-Drug Conjugates: Basic Concepts, Examples and Future Perspectives. *J. Controlled Release* **2012**, *161* (2), 422–428.
- (11) Farokhzad, O. C.; Langer, R. Impact of Nanotechnology on Drug Delivery. *ACS Nano* **2009**, *3* (1), 16–20.
- (12) Kwitniewski, M.; Juzeniene, A.; Glosnicka, R.; Moan, J. Immunotherapy: A Way to Improve the Therapeutic Outcome of Photodynamic Therapy? *Photochem. Photobiol. Sci.* **2008**, *7* (9), 1011–1017.
- (13) Sour, A.; Jenni, S.; Orti-Suarez, A.; Schmitt, J.; Heitz, V.; Bolze, F.; de Sousa, P. L.; Po, C.; Bonnet, C. S.; Pallier, A.; Toth, E.; Ventura, B. Four Gadolinium(III) Complexes Appended to a Porphyrin: A Water-Soluble Molecular Theranostic Agent with Remarkable Relaxivity Suited for MRI Tracking of the Photosensitizer. *Inorg. Chem.* **2016**, *55* (9), 4545–4554.
- (14) Goswami, L. N.; White, W. H.; Sperryak, J. A.; Ethirajan, M.; Chen, Y. H.; Missert, J. R.; Morgan, J.; Mazurchuk, R.; Pandey, R. K. Synthesis of Tumor-Avid Photosensitizer-Gd(III)DTPA Conjugates: Impact of the Number of Gadolinium Units in T-1/T-2 Relaxivity, Intracellular localization, and Photosensitizing Efficacy. *Bioconjugate Chem.* **2010**, *21* (5), 816–827.
- (15) Sperryak, J. A.; White, W. H.; Ethirajan, M.; Patel, N. J.; Goswami, L.; Chen, Y. H.; Turowsky, S.; Missert, J. R.; Batt, C.; Mazurchuk, R.; Pandey, R. K. Hexylether Derivative of Porphorphorbide-a (HPPH) on Conjugating with 3Gadolinium(III) Amino-benzyl-diethylenetriaminepentaacetic Acid Shows Potential for in Vivo Tumor Imaging (MR, Fluorescence) and Photodynamic Therapy. *Bioconjugate Chem.* **2010**, *21* (5), 828–835.
- (16) Song, Y.; Zong, H.; Trivedi, E. R.; Vesper, B. J.; Waters, E. A.; Barrett, A. G. M.; Radosevich, J. A.; Hoffman, B. M.; Meade, T. J. Synthesis and Characterization of New Porphyrazine-Gd(III) Conjugates as Multimodal MR Contrast Agents. *Bioconjugate Chem.* **2010**, *21* (12), 2267–2275.
- (17) Luo, J.; Chen, L. F.; Hu, P.; Chen, Z. N. Tetranuclear Gadolinium(III) Porphyrin Complex as a Theranostic Agent for Multimodal Imaging and Photodynamic Therapy. *Inorg. Chem.* **2014**, *53* (8), 4184–4191.
- (18) Aydın Tekdas, D.; Garifullin, R.; Senturk, B.; Zorlu, Y.; Gundogdu, U.; Atalar, E.; Tekinay, A. B.; Chernonosov, A. A.; Yerli, Y.; Dumoulin, F.; Guler, M. O.; Ahsen, V.; Gurek, A. G. Design of a Gd-DOTA-Phthalocyanine Conjugate Combining MRI Contrast Imaging and Photosensitization Properties as a Potential Molecular Theranostic. *Photochem. Photobiol.* **2014**, *90* (6), 1376–1386.
- (19) Haroon-Ur-Rashid; Umar, M. N.; Khan, K.; Anjum, M. N.; Yaseen, M. Synthesis and relaxivity measurement of porphyrin-based Magnetic Resonance Imaging (MRI) contrast agents. *J. Struct. Chem.* **2014**, *55* (5), 910–915.
- (20) Ke, X. S.; Tang, J.; Yang, Z. S.; Zhang, J. L. Beta-Conjugation of Gadolinium(III) DOTA Complexes to Zinc(II) Porpholactol as Potential Multimodal Imaging Contrast Agents. *J. Porphyrin Phthalocyanin* **2014**, *18* (10–11), 950–959.
- (21) Yuzhakova, D. V.; Lermontova, S. A.; Grigoryev, I. S.; Muravieva, M. S.; Gavrina, A. I.; Shirmanova, M. V.; Balalaeva, I. V.; Klapshina, L. G.; Zagaynova, E. V. *In Vivo* Multimodal Tumor Imaging and Photodynamic Therapy with Novel Theranostic Agents Based on the Porphyrazine Framework-Chelated Gadolinium (III) Cation. *BBA-Gen. Subjects* **2017**, *1861* (12), 3120–3130.
- (22) Jenni, S.; Bolze, F.; Bonnet, C. S.; Pallier, A.; Sour, A.; Toth, E.; Ventura, B.; Heitz, V. Synthesis and *In Vitro* Studies of a Gd(DOTA)-Porphyrin Conjugate for Combined MRI and Photodynamic Treatment. *Inorg. Chem.* **2020**, *59* (19), 14389–14398.
- (23) Schmitt, J.; Jenni, S.; Sour, A.; Heitz, V.; Bolze, F.; Pallier, A.; Bonnet, C. S.; Toth, E.; Ventura, B. A Porphyrin Dimer-GdDOTA Conjugate as a Theranostic Agent for One- and Two-Photon Photodynamic Therapy and MRI. *Bioconjugate Chem.* **2018**, *29* (11), 3726–3738.
- (24) Schmitt, J.; Heitz, V.; Sour, A.; Bolze, F.; Kessler, P.; Flamigni, L.; Ventura, B.; Bonnet, C. S.; Toth, E. A Theranostic Agent Combining a Two-Photon-Absorbing Photosensitizer for Photodynamic Therapy and a Gadolinium(III) Complex for MRI Detection. *Chem.—Eur. J.* **2016**, *22* (8), 2775–2786.
- (25) Higashino, T.; Nakatsuji, H.; Fukuda, R.; Okamoto, H.; Imai, H.; Matsuda, T.; Tochio, H.; Shirakawa, M.; Tkachenko, N. V.; Hashida, M.; Murakami, T.; Imahori, H. Hexaphyrin as a Potential Theranostic Dye for Photothermal Therapy and F-19 Magnetic Resonance Imaging. *ChemBioChem.* **2017**, *18* (10), 951–959.
- (26) Helm, L.; Merbach, A. E.; Tóth, E. v. *The chemistry of contrast agents in medical magnetic resonance imaging*, Second ed.; John Wiley & Sons Inc.: Hoboken, NJ, 2013; p xvi, 496 pages.
- (27) Clough, T. J.; Jiang, L. J.; Wong, K. L.; Long, N. J. Ligand Design Strategies to Increase Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents. *Nat. Commun.* **2019**, *10*, 1420.
- (28) Angelovski, G. What We Can Really Do with Bioresponsive MRI Contrast Agents. *Angew. Chem.-Int. Ed.* **2016**, *55* (25), 7038–7046.
- (29) Li, H.; Meade, T. J. Molecular Magnetic Resonance Imaging with Gd(III)-Based Contrast Agents: Challenges and Key Advances. *J. Am. Chem. Soc.* **2019**, *141* (43), 17025–17041.
- (30) Zang, L. X.; Zhao, H. M.; Hua, J. Y.; Qin, F.; Zheng, Y. D.; Zhang, Z. G.; Cao, W. W. Water-Soluble Gadolinium Porphyrin as a Multifunctional Theranostic Agent: Phosphorescence-Based Oxygen Sensing and Photosensitivity. *Dyes Pigments* **2017**, *142*, 465–471.
- (31) Wu, B.; Li, X. Q.; Huang, T.; Lu, S. T.; Wan, B.; Liao, R. F.; Li, Y. S.; Baidya, A.; Long, Q. Y.; Xu, H. B. MRI-Guided Tumor Chemo-Photodynamic Therapy with Gd/Pt Bifunctionalized Porphyrin. *Biomater. Sci.* **2017**, *5* (9), 1746–1750.
- (32) Ni, Y. Metalloporphyrins and Functional Analogues as MRI Contrast Agents. *Curr. Med. Imaging* **2008**, *4* (2), 96–112.
- (33) Schneider, C. A.; Rasband, W. S.; Eliceiri, K. W. NIH Image to ImageJ: 25 Years of Image Analysis. *Nat. Methods* **2012**, *9* (7), 671–5.
- (34) Schrödinger Release 2019-3: MacroModel; Schrödinger, LLC: New York, NY, 2019.
- (35) Harder, E.; Damm, W.; Maple, J.; Wu, C.; Reboul, M.; Xiang, J. Y.; Wang, L.; Lupyan, D.; Dahlgren, M. K.; Knight, J. L.; Kaus, J. W.; Cerutti, D. S.; Krilov, G.; Jorgensen, W. L.; Abel, R.; Friesner, R. A. OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. *J. Chem. Theory Comput.* **2016**, *12* (1), 281–96.
- (36) Horvath, O.; Huszank, R.; Valicsek, Z.; Lendvay, G. Photophysics and Photochemistry of Kinetically Labile, Water-Soluble Porphyrin Complexes. *Coord. Chem. Rev.* **2006**, *250* (13–14), 1792–1803.
- (37) De Luca, G.; Romeo, A.; Scolaro, L. M.; Ricciardi, G.; Rosa, A. Sitting-Atop Metallo-Porphyrin Complexes: Experimental and Theoretical Investigations on Such Elusive Species. *Inorg. Chem.* **2009**, *48* (17), 8493–8507.
- (38) Powell, D. H.; Dhubhghaill, O. M. N.; Pubanz, D.; Helm, L.; Lebedev, Y. S.; Schlaepfer, W.; Merbach, A. E. Structural and Dynamic Parameters Obtained from ¹⁷O NMR, EPR, and NMRD Studies of Monomeric and Dimeric Gd³⁺ Complexes of Interest in Magnetic Resonance Imaging: An Integrated and Theoretically Self Consistent Approach. *J. Am. Chem. Soc.* **1996**, *118* (39), 9333–9346.

(39) Baptista, M. S.; Cadet, J.; Di Mascio, P.; Ghogare, A. A.; Greer, A.; Hamblin, M. R.; Lorente, C.; Nunez, S. C.; Ribeiro, M. S.; Thomas, A. H.; Vignoni, M.; Yoshimura, T. M. Type I and Type II Photosensitized Oxidation Reactions: Guidelines and Mechanistic Pathways. *Photochem. Photobiol.* **2017**, *93* (4), 912–919.

(40) Yamakoshi, Y.; Umezawa, N.; Ryu, A.; Arakane, K.; Miyata, N.; Goda, Y.; Masumizu, T.; Nagano, T. Active Oxygen Species Generated from Photoexcited Fullerene (C₆₀) as potential medicines: O₂^{•-} versus ¹O₂. *J. Am. Chem. Soc.* **2003**, *125* (42), 12803–12809.

(41) Liosi, K.; Stasyuk, A. J.; Masero, F.; Voityuk, A. A.; Nausser, T.; Mougel, V.; Sola, M.; Yamakoshi, Y. Unexpected Disparity in Photoinduced Reactions of C₆₀ and C₇₀ in Water with the Generation of O₂^{•-} or ¹O₂. *JACS Au* **2021**, *1* (10), 1601–1611.

(42) Lion, Y.; Delmelle, M.; Vandevorst, A. New Method of Detecting Singlet Oxygen Production. *Nature* **1976**, *263* (5576), 442–443.

(43) In our preliminary results, it was shown that Gd-1 reveals stabilization of some of the G4 motifs such as a c-MYC-derived G4 sequence (data is not shown).

(44) Yoshizawa-Sugata, N.; Masai, H. Human Tim/Timeless-Interacting Protein, Tipin, is Required for Efficient Progression of S Phase and DNA Replication Checkpoint. *J. Biol. Chem.* **2007**, *282* (4), 2729–40.

(45) Yoshizawa-Sugata, N.; Masai, H. Roles of Human AND-1 in Chromosome Transactions in S Phase. *J. Biol. Chem.* **2009**, *284* (31), 20718–20728.